FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage
A Prospective, Blinded, Randomised Clinical Trial of Fludrocortisone Compared With Placebo in Critically Ill Patients Presenting With Aneurysmal Subarachnoid Haemorrhage
The George Institute
524 participants
Aug 13, 2025
INTERVENTIONAL
Conditions
Summary
A multi-centre, prospective, blinded, randomised clinical trial of fludrocortisone compared with placebo in patients presenting with aneurysmal subarachnoid haemorrhage. The study aim is to determine if early administration of enteral fludrocortisone in aneurysmal subarachnoid haemorrhage reduce death and dependency at six months.
Eligibility
Inclusion Criteria5
- Age 18 years or older
- Diagnosed with subarachnoid haemorrhage from an aneurysm confirmed on computed tomography angiography (CTA) or digital subtraction angiography (DSA) of the intra-cranial arteries
- Aneurysm has been secured
- Hospital admission for aSAH within 96 hours
- Currently being treated in a critical care environment
Exclusion Criteria8
- Unable to receive enteral medications
- Pre-existing glucocorticoid or mineralocorticoid treatment
- Previous allergic reaction to fludrocortisone
- History of cardiac, hepatic, or renal failure
- Hypernatremia or hyponatremia (Na\>145mmol/L or Na\<125mmol/L) on the most recent blood sample at the time of screening.
- Death deemed imminent or inevitable
- Pregnancy (confirmed or suspected)
- Previous inclusion in the FLASH trial
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
small white tablet containing 100mcg of fludrocortsone
Matched placebo tablet,
Locations(16)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06409364